- A booster dose of an inactivated SARS-CoV-2 vaccine increases
- 2 neutralizing antibodies and T cells that recognize Delta and
- 3 Omicron variants of concern.

- 4 Bárbara M Schultz<sup>1,#</sup>, Felipe Melo-González<sup>1,#</sup>, Luisa F Duarte<sup>1,#</sup>, Nicolás MS
- 5 Gálvez<sup>1,#</sup>, Gaspar A Pacheco<sup>1,#</sup>, Jorge A Soto<sup>1,#</sup>, Roslye V Berríos-Rojas<sup>1,2</sup>, Liliana
- 6 A González<sup>1,2</sup>, Daniela Moreno-Tapia<sup>1,2</sup>, Daniela Rivera-Pérez<sup>1,2</sup>, Mariana Ríos<sup>1,2</sup>,
- 7 Yaneisi Vázquez<sup>1,2</sup>, Guillermo Hoppe-Elsholz<sup>1,2</sup>, Omar P Vallejos<sup>1,2</sup>, Carolina
- 8 Iturriaga<sup>3</sup>, Marcela Urzua<sup>3</sup>, María S Navarrete<sup>4</sup>, Álvaro Rojas<sup>4</sup>, Rodrigo Fasce<sup>5</sup>,
- 9 Jorge Fernández<sup>5</sup>, Judith Mora<sup>5</sup>, Eugenio Ramírez<sup>5</sup>, Aracelly Gaete-Argel<sup>1,6</sup>,
- 10 Mónica Acevedo<sup>1,6</sup>, Fernando Valiente-Echeverría<sup>1,6</sup>, Ricardo Soto-Rifo<sup>1,6</sup>, Daniela
- 11 Weiskopf<sup>7</sup>, Alba Grifoni<sup>7</sup>, Alessandro Sette<sup>7,8</sup>, Gang Zeng<sup>9</sup>, Weining Meng<sup>9</sup>,
- 12 CoronaVac03CL Study Group, José V González-Aramundiz<sup>10</sup>, Pablo A
- González<sup>1,2</sup>, Katia Abarca<sup>1,3</sup>, Alexis M Kalergis\*<sup>1,2,11</sup>, Susan M Bueno\*<sup>1,2</sup>

#### Affiliations:

14

- <sup>1</sup>Millennium Institute on Immunology and Immunotherapy, Santiago, Chile.
- <sup>2</sup>Departamento de Genética Molecular y Microbiología, Facultad de Ciencias
- 18 Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile.
- <sup>3</sup>Departamento de Enfermedades Infecciosas e Inmunología Pediátrica, División
- 20 de Pediatría, Escuela de Medicina, Pontificia Universidad Católica de Chile,
- 21 Santiago, Chile. <sup>4</sup>Departamento de Enfermedades Infecciosas del Adulto, División
- 22 de Medicina, Escuela de Medicina, Pontificia Universidad Católica de Chile,
- 23 Santiago, Chile. <sup>5</sup>Departamento de Laboratorio Biomédico, Instituto de Salud

24 Pública de Chile. <sup>6</sup>Laboratorio de Virología Molecular y Celular, Programa de 25 Virología, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de 26 Chile, Santiago, Chile. <sup>7</sup>Center for Infectious Disease and Vaccine Research, La 27 Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA. 8Department of 28 Medicine, Division of Infectious Diseases and Global Public Health, University of 29 California, San Diego (UCSD), La Jolla, CA 92037, USA. 9Sinovac Biotech, Beijing, China. <sup>10</sup>Departamento de Farmacia, Facultad de Química y de Farmacia, 30 31 Pontificia Universidad Católica de Chile, Santiago, Chile. <sup>11</sup>Departamento de 32 Endocrinología, Facultad de Medicina, Escuela de Medicina, Pontificia Universidad 33 Católica de Chile, Santiago, Chile.

- 35 #These authors contributed equally to this work.
- 37 \*Corresponding authors.
- 38 **Keywords**:

34

36

- 39 CoronaVac; Phase 3 clinical trial; SARS-CoV-2; COVID-19; inactivated vaccine,
- 40 Booster dose.

#### **Abstract**

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

Background: Corona Vac® is an inactivated SARS-CoV-2 vaccine approved by the World Health Organization. Previous studies reported increased levels of neutralizing antibodies and specific T cells two- and four-weeks after two doses of CoronaVac<sup>®</sup>, but the levels of neutralizing antibodies are reduced at six to eight months after two doses. Here we report the effect of a booster dose of CoronaVac® on the anti-SARS-CoV-2 immune response generated against variants of concern (VOC) Delta and Omicron in adults participating in a phase 3 clinical trial in Chile. Methods: Volunteers immunized with two doses of CoronaVac® in a four-week interval received a booster dose of the same vaccine between twenty-four and thirty weeks after the 2nd dose. Four weeks after the booster dose, neutralizing antibodies and T cell responses were measured. Neutralization capacities and T cell activation against VOC Delta and Omicron were detected at four weeks after the booster dose. Findings: We observed a significant increase in neutralizing antibodies at four weeks after the booster dose. We also observed an increase in CD4<sup>+</sup> T cells numbers over time, reaching a peak at four weeks after the booster dose. Furthermore, neutralizing antibodies and SARS-CoV-2 specific T cells induced by the booster showed activity against VOC Delta and Omicron. Interpretation: Our results show that a booster dose of CoronaVac<sup>®</sup> increases the anti-SARS-CoV-2 humoral and cellular immune responses in adults. Immunity induced by a booster dose of CoronaVac<sup>®</sup> is active against VOC, suggesting an effective protection.

## **Background**

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

The ongoing pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has promoted the rapid development of safe, immunogenic, and effective vaccines against SARS-CoV-2 to be used by the general population, which have successfully reduced the transmission of the disease burden. CoronaVac<sup>®</sup> is an inactivated SARS-CoV-2 vaccine developed by Sinovac Life Sciences Co., Ltd. (Beijing, China) and is among the current vaccines approved by the World Health Organization (WHO) to combat coronavirus disease 2019 (COVID-19) and one of the most used vaccines worldwide<sup>1,2</sup>. Phase I/II clinical trials in China demonstrated that this vaccine induces cellular and humoral response upon immunization 3-5. Furthermore, the ongoing phase 3 clinical trial in Chile has described an increase in the levels of IgG and neutralizing antibodies in adults aged 18-59 years and ≥ 60 years two- and four-weeks after the second dose of CoronaVac<sup>® 56</sup>. In addition, this vaccination promotes the activation of a T cell immune response against SARS-CoV-2 antigens in a 0-14 immunization schedule <sup>5</sup> (two-weeks interval), being an effective vaccine to prevent COVID-19 <sup>7,8</sup>. In Chile, 93.7% of the target population has received a first vaccine dose, and 91.4% were fully vaccinated with CoronaVac® on December 10th of 2021 in a 0-28 days vaccination schedule <sup>9</sup>. Although this primary immunization schedule induces neutralizing antibody present in the serum of vaccinated people <sup>10</sup>, these titers decrease in time 6,11,12 and have lower levels of neutralization against highly transmissible variants of concern (VOC) as compared to the original vaccine strain, potentially decreasing the effectiveness of these vaccines as new variants emerge <sup>13–17</sup>. For these reasons, the use of booster doses was approved in Chile in August 2021 in Chile for high-risk populations and adults at five months after administration of the second dose <sup>18</sup>. In this sense, a report published in October 2021 in Chile, showed that the effectiveness of CoronaVac® against COVID-19 increase from 56% to 80% fourteen days after the application of the booster dose <sup>19</sup>. Notably, a previous study performed in adults aged 18-59 years old demonstrated that a booster dose of CoronaVac<sup>®</sup>, applied six months after the first dose to individuals that previously received two doses of this vaccine, increased the levels of antibodies 3-5-fold as compared to the levels observed four weeks after the second dose <sup>12</sup>. Here, we further extend these findings by reporting the levels of neutralizing antibodies and specific T cells against SARS-CoV-2 and its activity against VOC Delta and Omicron in adults ≥18 years old that participated in the phase 3 clinical trial carried out in Chile, who were vaccinated in a 0-28-days vaccination schedule and received a booster dose five months after the second dose.

#### **Materials and methods**

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

#### **Volunteers and sample collection**

Blood samples were obtained from volunteers recruited in the clinical trial CoronaVac03CL (clinicaltrials.gov #NCT04651790) carried out in Chile starting in November 2020. The Institutional Scientific Ethical Committee of Health Sciences reviewed and approved the study protocol at the Pontificia Universidad Católica de Chile (#200708006). Trial execution was approved by the Chilean Public Health Institute (#24204/20) and was conducted according to the current Tripartite

Guidelines for Good Clinical Practices, the Declaration of Helsinki <sup>20</sup>, and local regulations. Informed consent was obtained from all volunteers upon enrollment. Volunteers receive two doses of CoronaVac® (3 µg or 600SU of inactivated SARS-CoV-2 inactivated along with alum adjuvant) in a four-week interval (0-28-day immunization schedule) and then a booster dose five months after the second dose. A complete inclusion and exclusion criteria list have been reported <sup>5</sup>. On November 11<sup>th</sup>, 2021, one hundred and eighty-six volunteers in the immunogenicity branch received the booster dose. The antibody and cell mediated immune responses were evaluated volunteers that had completed all their previous visits in one of the centers of the study (**Figure 1A**). Blood samples were obtained from all the volunteers before administration of the first dose (pre-immune), two, four, and twenty weeks (or five months) after the second dose, and four weeks after the booster dose (**Figure 1B**).

#### **Procedures**

The presence of antibodies against RBD with neutralizing capacities were measured in sera from seventy-seven volunteers that had completed all their study visits, including one month after the booster dose of CoronaVac<sup>®</sup>. The neutralizing capacities of circulating antibodies were evaluated by a surrogate virus neutralization test (sVNT) (Genscript Cat#L00847-A). Samples were two-fold serially diluted starting at a 4-fold dilution until reaching a 512-fold dilution. Assays were performed according to the instructions of the manufacturer and as reported previously <sup>5</sup>. Neutralizing antibody titers were determined as the last fold dilution in which the interaction between hACE2 and RBD was inhibited by 30% or more. Samples with a percentage of inhibition ≤30% at the lowest dilution (1:4) were

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

assigned as seronegative with a titer of 2. A sample was considered seropositive when its titer was higher than the pre-immune titer. The percentage of inhibition was determined as: 100 \* [OD450nm value of negative control - OD450nm value of sample] / [OD450nm of negative control]. A standard curve was used to plot the neutralization response in the samples as international units (IU) using the WHO International Standard for SARS-CoV-2 antibody (NIBSC code 20/136), which was prepared according to the instructions of the manufacturer <sup>21</sup>. Data were analyzed using a sigmoidal curve model with a logarithm transformation of the concentration, and the final concentration for each sample was the average of the product of the interpolated IU from the standard curve and the sample dilution factor required to reach the OD450 value that falls within the linear range determined for each sample. Samples with undetermined concentration at the lowest dilution tested (1:4) were assigned to the lower limit of quantification (16.4 IU). The Geometric Mean Units (GMU) and titers (GMT) were represented in Figure 2 and Supplementary Figure 1, respectively. Table 2 shows comparisons among the visits. Conventional virus neutralization tests (cVNT) were performed in sixty-two of the previous seventy-seven volunteers and evaluated as previously reported 5. Briefly, Vero E6 cells were infected with a SARS-CoV-2 strain obtained by viral isolation in tissue cultures (33782CL-SARS-CoV-2 strain, D614G variant). Neutralization assays were carried out by the reduction of cytopathic effect (CPE) in Vero E6 cells (ATCC CRL-1586). The titer of neutralizing antibodies was defined as the highest serum dilution that neutralized virus infection, at which the CPE was

absent as compared with the virus control wells (cells with CPE). Vero E6 cells

were seeded in 96-well plates ( $4\times10^4$  cells/well). For neutralization assays, 100 µL of 33782CL-SARS-CoV-2 (at a dose of 100 TCID<sub>50</sub>) were incubated with serial dilutions of heat-inactivated sera samples (dilutions of 1:4, 1:8, 1:16, 1:32, 1:64, 1:128, 1:256, and 1:512) from participants for 1h at 37 °C. Cytopathic effect on Vero E6 cells was analyzed 7 days after infection.

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

A pseudotyped virus neutralization test (pVNT) assay was performed to assess the capacity of the antibodies against SARS-CoV-2 VOC in samples from thirty volunteers of the seventy-seven previously analyzed by sVNT. As previously reported <sup>14</sup>, a HIV-1 backbone expressing firefly luciferase as a reporter gene and pseudotyped with the SARS-CoV-2 spike glycoproteins (HIV-1-SΔ19) from from lineage B.1 (D614G) or variants Delta (T19R, del157/158, L452R, T478K, D614G, P681R, D950N) and Omicron (A67V, ΔH69-V70, T95I, Y145D, ΔG142 -V143-Y144, \( \Delta N211, \) EPE 213-214, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, T547K, D614G, H655Y, N679K, P681H, N764K, N865K, Q954H, N969K, L981F) was prepared as previously described <sup>22</sup>. Serum samples were two-fold diluted starting at 1:10 or 1:4 and the estimation of the ID80 was obtained using a 4-parameter nonlinear regression curve fit measured as the percent of neutralization determined by the difference in average relative light units (RLU) between test samples and pseudotyped virus controls. Also, cVNT assays were performed to assess the capacity of the antibodies against SARS-CoV-2 Delta variant in samples from nineteen volunteers of the seventy-seven previously analyzed by sVNT.

ELISPOT and flow cytometry assays were performed to evaluate the cellular immune response in forty volunteers of the seventy-seven previously analyzed

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

(Figure 1A), stimulating PBMCs with four Mega Pools (MPs) of peptides derived from the proteome of SARS-CoV-2 <sup>23</sup>: peptides from the S protein of SARS-CoV-2 (MP-S), the remaining proteins of the viral particle (excluding S protein peptides) (MP-R), and shorter peptides from the whole proteome of SARS-CoV-2 (MP-CD8-A and MP-CD8-B) <sup>23</sup>. Thirty of the previously analyzed volunteers were also stimulated with three Mega Pools (MP) of VOC, provided by La Jolla Institute for Immunology. MP derived from the S protein of SARS-CoV-2 WT, SARS-CoV-2 B1.617.2 MP 4326 (Delta variant), and SARS-CoV-2 B1.1.529 MP 4359 (Omicron variant) 14 were used to evaluate T cell activation at four weeks after the booster dose. Positive and negative controls were held for each assay. The number of Spot Forming Cells (SFC) for interferon gamma (IFN-γ) were determined by ELISPOT and the expression of Activation-Induced Markers (AIM) by T cells was evaluated by flow cytometry. Assays were performed according to the instructions of the manufacturer and as reported previously 5. Further details on the ELISPOT assay, antibodies used for flow cytometry, and the respective protocols can be found in the Supplementary information and **Supplementary Table 1**.

Interleukin 2 (IL-2) and IFN-γ secretion were evaluated in the supernatants of twenty-two volunteers previously stimulated for 20h with SARS-CoV-2 MP of peptides derived from the Spike protein of VOC, using a Luminex 200 xMap multiplex system (Luminex Corporation, Austin, TX). The limit of detection for the cytokine measured ranged from 4.2 to 13,390 pg/mL, according to manufacturer's instructions. Further experimental details can be found in **Supplementary Information**.

#### Statistical analyses

Statistical differences for the immunogenicity results considered repeated measures ANOVA with the Geisser-Greenhouse correction and Dunnet's *a posteriori* multiple tests to compare between the booster dose and the other visits. Analyses were performed over the base 10 logarithms of the data for neutralizing antibody by sVNT, cVNT and pVNT. Cellular immune responses were analyzed by a Friedman test for repeated measures for ELISPOT and flow cytometry for the comparisons between booster dose and the other visits. Secretion of cytokines were compared between the secretion induced by the WT strain against the VOC Delta and Omicron by repeated measures ANOVA. The significance level was set at 0.05 for all the analyses. All data were analyzed with GraphPad Prism 9.0.1.

#### Results

A booster dose of CoronaVac<sup>®</sup> induces a significant increase in antibody titers with neutralizing capacity in adults.

One hundred and eighty-six volunteers from the immunogenicity branch that received a booster dose of the CoronaVac<sup>®</sup> were included in this study. The first dose of the vaccine was inoculated from January to March of 2021, and the second dose was inoculated 28 days after the first one. The neutralizing capacity of serum antibodies was evaluated in seventy-seven and sixty-two volunteers by sVNT and cVNT, respectively, at the five different time-points indicated in **Figure 1B**.

As shown in **Figures 2A and D**, the peak level of antibodies with neutralizing capacity in the total population evaluated, tested by sVNT and cVNT,

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

is reached at two weeks after the second dose (GMU 168.0, 95% CI=19.5-34.2 and GMT, 95% CI=) and four weeks after the second dose (GMU 124.8, 95% CI=96.3-161.7 and GMT 13.5, 95% CI=9.6-19.2). However, this neutralizing capacity significantly decreased twenty weeks after the second dose (GMU 39.0. 95% CI=32.4-47.0 and GMT 8.3, 95% CI=9.6-19.2), which is in line with previous reports where the immunity against SARS-CoV-2 wanes six months after infection or vaccination <sup>24,25</sup>. After the booster dose, the neutralizing capacity of the antibodies increased even more than the one reported two weeks after the second dose (GMU 499.0, 95% CI=370.6-673.0 and GMT 89.5  $\pm$  64.0-125.2). Overall, we observed that four weeks after the booster dose the neutralizing capacity increased more than 12-fold (sVNT) and 10-fold (cVNT) as compared to the response at twenty weeks after the second dose, and almost 3-fold as compared to two weeks after the second dose (Figures 2A and D). In adults 18-59 years old, the neutralizing capacity of circulating antibodies tested by sVNT and cVNT (Figures 2B and E, respectively) reached its maximum four weeks after the booster dose (GMU 918.8, 95% CI=623.4-1354 and 176.9, 95% CI=111.7-280.1) increasing more than 18- and 12-fold as compared to five months after the second dose (GMU 48.9, 95% CI=37.6-63.5 and GMT 14.2, 95% CI=7.1-28.4) and more than 4-fold as compared to two weeks after the second dose (GMU 220.2, 95% CI=150.7-321.7 and GMT 17.5, 95% CI=9.8-31.3) (Figures 2B and E). The seropositivity rate in this group reached 100% at four weeks after the booster dose (Table 2). On the other hand, 53.2% of the total volunteers analyzed here were adults ≥60 years. In this group, the same tendency

was observed, as seen in **Figure 2C and F**, observing an increase in the level of neutralizing antibodies evaluated by both techniques of more than 9-fold at four weeks after the booster dose (GMU 300.5, 95% CI=203.5-443.6 and GMT 47.3, 95% CI=32.1-69.5) as compared to the response observed twenty weeks after the second dose (GMU 32.4, 95% CI=25.1-41.8 and GMT 5.0, 95% CI=3.5-7.0). Equivalent to the 18-59 years old group, the seropositivity rate in this age group reached 100% four weeks after the booster dose (**Table 2**). The seropositivity rate achieved at four weeks after the booster dose was the highest when compared with the other visits in this study in the total vaccinated group and in both groups analyzed.

# A booster dose of CoronaVac<sup>®</sup> induces a robust cellular immune response in adults.

The cellular responses following a booster dose of CoronaVac® were evaluated in 40 volunteers. We observed that CD4+ T cell activation was increased twenty weeks after the second dose as compared to the other time points in both age groups, suggesting that CoronaVac® can stimulate CD4+ T cell responses that are sustained over time (Figure 3A-C). Importantly, we observed a significantly further increase in CD4+ T cell activation in both age groups following the booster dose, as compared to the pre-immune sample and samples obtained at two and four weeks after the second dose (Figure 3A-C). However, this difference was not significant as compared to the sample obtained twenty weeks after the second dose (Figure 3A-C). Moreover, we did not observe a significant increase in the expression of AIM by CD8+ T cells following the booster dose as compared to any

other time point, suggesting that specific CD8<sup>+</sup> T cell responses induced by CoronaVac<sup>®</sup> are not detected with the current methodologies, even after a third dose (**Supp. Figure 2A and C**). Accordingly, we observed an increase in IFN-γ production upon stimulation with mega-pools of peptides (MPs) S and R by ELISPOT at four weeks after the booster dose for both groups, as compared to the pre-immune sample (**Figure 3D-F**). As in the case of flow cytometry, we did not observe significant increase of IFN-γ<sup>+</sup> SFCs upon stimulation with CD8 MPs at any time point (**Supp. Figure 2**). These results suggest that although humoral responses decrease over time following vaccination with CoronaVac<sup>®</sup>, CD4<sup>+</sup> T cell responses remain significantly increased as compared to pre-immune samples and the booster dose promotes a small increase both IFN-γ production and CD4<sup>+</sup> T cell activation that is not significantly different as compared to the levels observed 20 weeks after the second dose.

# Neutralizing antibodies and specific T cells induced by a booster dose of CoronaVac® recognize Delta and Omicron variants of SARS-CoV-2.

As we observed that the neutralization capacity and the T cell responses increased significantly with the booster dose and knowing that vaccinated volunteers exhibit decreased neutralization against VOC<sup>14</sup>, we proceeded to evaluate the neutralizing capacities of antibodies in the serum from thirty booster-vaccinated individuals in pseudotyped virus neutralization test (pVNT) assay against two variants of concern of SARS-CoV-2, comparing with the level obtained for the D614G SARS-CoV-2 variant (B.1 lineage, **Figure 4A-B**). We observed that

the titers of antibodies with neutralizing capacities against Delta and Omicron variant show a significant reduction as compared to the levels achieved for the D61G variant (D614G: GMT 241.8, CI=155.7-375.6, Delta: 159.2, CI=99.1-256.0 and Omicron: GMT 50.7, CI=30.4-84.8), with a reduction of 1.5 for Delta and 4.8 for Omicron (Figure 4A). However, when we compared the changes in seropositivity for Delta and Omicron (Figure 4B), we observed a 93% and 76.7%, respectively, following the booster dose (Table 3). Neutralization assays against Delta variant with a cVNT in a different group of nineteen volunteers also show that antibodies induced four weeks after the booster dose have reduced capacity to neutralize this VOC (Supp Figure 4A), although the seropositivity rate observed is 84% (Supp Figure 4B).

The cellular responses for VOC following a booster dose of CoronaVac® were also evaluated in thirty volunteers using MPs of peptides derived from the Spike protein of Delta and Omicron variants. We observed equivalent numbers of AIM by CD4+T cells after four weeks of the booster dose upon stimulation with MP-S of SARS-CoV-2 WT, Delta, or Omicron variant (Figure 5A), with no significant differences between the response against the MP-S of the variants as compared to the MP-S of the WT strain. IFN-γ secreting T cells were also analyzed in these samples and no differences were observed (Figure 5B). We also quantified the production of different cytokines in the supernatant of PBMCs stimulated with the MP-s of WT, Delta, and Omicron variants, observing that at four weeks after the booster dose the stimulated cells secrete equivalent levels of IL-2 and IFN-γ (Figure Supp 3). These results suggest that although the humoral response

measured as neutralization capacities and seroconversion against these VOC is lower as compared to the humoral response against the D614G strain, the cellular responses against SARS-CoV-2 VOC is equivalent to the responses elicited by the wild type strain in volunteers vaccinated with booster dose.

#### Discussion

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

In this report we evaluated the humoral and cellular immune response generated four weeks after the application of a booster dose of inactivated CoronaVac® vaccine in a cohort of volunteers enrolled in the phase 3 clinical trial held in Chile. The data reported here showed that although there was an adequate humoral response after two doses of CoronaVac®, with a 65.9% of effectiveness in preventing COVID-19 8, both the sVNT and cVNT assays showed a decrease in the GMT of neutralizing capacities of circulating antibodies against SARS-CoV2 twenty weeks after the second dose (Figure 2). Due to this decrease in neutralizing capacities, a booster dose of CoronaVac® was evaluated in a clinical study in China, showing promising results in enhanced humoral immune responses<sup>12,26</sup>. The evaluation of the immune response reported here shows that after the booster dose, the neutralizing titers and seroconversion rates increase in the whole group, to a higher extent than two weeks after the second dose, where the peak in neutralization was previously observed, which is in line with the observed by Clemens et al., 15. Also, we observed a steady activation of the CD4+ T cells and secretion of IFN- $\gamma$  during the time-points evaluated (**Figure 3**).

Since the neutralizing antibody titers correlated with protection against SARS-CoV-2 infection <sup>10</sup>, these results likely imply a better outcome and protection against COVID-19, as reported in previous studies performed in Israel that showed a decrease in the transmission and the disease severity disease by this virus twelve or more days after booster inoculation. In Chile, the effectiveness and prevention in hospitalization increased when assessed fourteen days after the booster dose of CoronaVac<sup>®</sup> <sup>19,27</sup>. Another study, performed with a booster dose of CoronaVac<sup>®</sup>, showed that an additional dose result in good neutralization capacity against parental SARS-CoV-2 and against Delta variant four weeks after the booster dose, generating a long-lasting humoral response, which was due to an enhancement of the memory immune response generated by B cells <sup>26</sup>.

Adults ≥60 years old produced lower levels of antibodies with neutralizing capacities than the whole group during this study, which was also described previously (**Figure 2C and F**) <sup>5</sup>. This result is in line with previous data reported for a population vaccinated in Chile <sup>6</sup>, among hospital workers who received two doses of CoronaVac<sup>®</sup> <sup>28</sup>, and in a study with the mRNA-1273 vaccine <sup>29</sup>. In this sense, our results are equivalent to those described in a phase I/II of the clinical trial performed with CoronaVac<sup>®</sup> in China, showing that the neutralizing antibody titers in this group decreased at five months after the second dose and that a booster dose is required 6-8 months after the first vaccination to rapidly increase and maintain the neutralizing antibody titers <sup>30</sup>.

In the case of the T cell response (**Figure 3**), other studies have shown that Pfizer BNT162b2 and mRNA-1273 induce durable CD4<sup>+</sup> T cell activation and cytokine production up to six months following vaccination, but it remains to be

elucidated whether expression of AIM by CD4<sup>+</sup> T cells and cytokine production further increase following a booster dose with these vaccines <sup>31,32</sup>. Here, we observed that the activation of CD4<sup>+</sup> T cells and IFN-γ production stays increased up to twenty weeks after the second dose, and after the booster dose both parameters increased in the 18-59 years old group and was maintained at the levels observed twenty weeks after the second dose in adults ≥60 years old. In contrast to BNT162b2 and mRNA-1273 vaccines, CoronaVac<sup>®</sup> delivers not only the Spike protein upon immunization but also other viral antigens, which may explain why vaccinated individuals still display AIM<sup>+</sup> CD4<sup>+</sup> T cells five months after the second dose, regardless of a third dose.

When the neutralization capacity analyzed by pVNT of the VOC Delta and Omicron was evaluated four weeks after the booster dose, we observed differences in the neutralization capacity as compared to the D614G variant (lineage B.1), which does not exhibit mutations in the RBD of the S1 protein (Figure 4 and table 3). We previously reported that CoronaVac® is able to induce neutralization against the Delta variant at 4 weeks after the second dose, although to a lesser extent compared to the WT strain <sup>14</sup>. Another study recently reported a significant increase in the neutralizing capacity after a booster dose with CoronaVac® for the Delta variant, as compared to the levels observed in volunteers vaccinated with two doses <sup>26,33</sup>. Although we did not observe similar levels of enhanced neutralization against the variants Delta after the booster dose using pVNT (Figure 4A), the seropositivity against Delta variant is almost 100% (Figure 4B)<sup>33</sup>. Here, we also show that a booster dose induces neutralization against the

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

variant Omicron, which has rapidly spread worldwide and is the predominant circulating variant to date <sup>34</sup>. The high number of mutations described in the RBD of this variant has been associated with increased evasion of neutralizing responses in either unvaccinated or vaccinated subjects <sup>34,35</sup>. Although the neutralization observed in subjects vaccinated with a booster dose of CoronaVac® is significantly lower to the observed against the D614G variant, we observed a seropositivity of 76.7% following the booster, suggesting some degree of protection in most of the vaccinees. In this sense, it has been reported that a heterologous schedule of vaccination may induce a higher neutralization ability and a better neutralization against variants of concern as Delta 36 and Omicron 16. In line with this, a heterologous vaccination with CoronaVac® and a booster dose of Pfizer BNT162b2 showed a good neutralization titer against VOC Delta and Omicron, with respect to the ancestral virus <sup>16</sup>. Similarly, a comparison between heterologous and homologous booster schedules after the vaccination with CoronaVac®, shows an increase in neutralization against the VOC Delta and Omicron<sup>15</sup>. There are discrepancies between the results in neutralization titers, which can be attributed to the neutralization assays performed and/or the study population; however, important booster responses are observed in these studies, and seropositivity reached after the booster dose of CoronaVac® against VOC are also similar <sup>16</sup>.

In the case of the cellular response, this is the first report to characterize CD4<sup>+</sup> T cell responses following a booster dose of CoronaVac<sup>®</sup> against the Omicron variant of SARS-CoV2. Previous studies using the same MP from VOC evaluated here have shown that CD4<sup>+</sup> T cells respond to VOC in a similar extent as compared to the ancestral strain in individuals vaccinated with CoronaVac<sup>®</sup> <sup>14,37</sup>

and mRNA vaccines, which has been explained by the high conservation of T cell epitopes. In this sense, the booster dose of CoronaVac® induces the expression of CD4+ T cell activation markers and secretion of IFN-γ and IL-2 against the VOC Delta and Omicron, which is comparable to the response generated against the WT strain (**Figure 5**). In line with this, a recent study has shown that T cell responses against the ancestral strain are cross-reactive against the Omicron variant in convalescent individuals and volunteers vaccinated with Pfizer BNT162b2 <sup>38</sup>, supporting the idea that the induction of T cell responses against the ancestral strain may be protective against the Omicron variant.

Our report shows that the booster dose of CoronaVac<sup>®</sup> in a 0-28 days schedule induces antibodies with neutralizing capacities, which are higher than the levels observed at 2- and 4-weeks after the second dose, generating an increased humoral response even in adults ≥60 years old. Besides this, our results suggest that a third dose of CoronaVac<sup>®</sup> supports CD4<sup>+</sup> T cell activation, which may confer either protection or enhanced immune responses against the virus and prevent severe disease following exposure to SARS-CoV-2 exposure. Importantly, the humoral and cellular immune response promoted by a booster dose of CoronaVac shows activity against Delta and Omicron variants and probably results in better effectiveness of this vaccine during predominance of these VOC.

#### Limitations

This study presents several limitations, such as the reduced sample size for the assays and the absence of data for neutralization against Omicron variant with a conventional viral neutralization test. The assessment of total antibody response against Spike proteins and other SARS-CoV-2 proteins would also add additional information about the humoral immune response against SARS-CoV-2 after the booster dose. Due to the limit of quantification of the technique, samples with undetermined concentration at the lowest dilution tested (1:4) were assigned the lower limit of quantification (16.4 IU) and other neutralization assays.

#### **Funding**

The CoronaVac03CL Study was funded by The Ministry of Health, Government of Chile, the Confederation of Production and Commerce (CPC), Chile and SINOVAC Biotech. NIH NIAID, under Contract 75N93021C00016, supports AS and Contract 75N9301900065 supports AS, AG and DW. The National Agency for Research and Development (ANID) through the Fondo Nacional de Desarrollo Científico y Tecnológico (FONDECYT) grants Nº 1190156 and Nº 1211547 supports RSR and FVE, respectively. The Millennium Institute on Immunology and Immunotherapy, ANID - Millennium Science Initiative Program ICN09\_016 (former P09/016-F) supports RSR, VFE, SMB, KA, PAG and AMK; The Innovation Fund for Competitiveness FIC-R 2017 (BIP Code: 30488811-0) supports SMB, PAG and AMK.

#### **Competing interests**

ZG and MW are SINOVAC Biotech employees and contributed to the conceptualization of the study (clinical protocol and eCRF design) and did not participate in the analysis or interpretation of the data presented in the manuscript.

A.S. is a consultant for Gritstone, Flow Pharma, Arcturus, Immunoscape, 463 464 CellCarta, OxfordImmunotech and Avalia, La Jolla Institute for Immunology (LJI) 465 has filed for patent protection for various aspects of T cell epitope and vaccine 466

design work. All other authors declare no conflict of interest.

### **Acknowledgments**

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

We would like to thank the support of the Ministry of Health, Government of Chile; Ministry of Science, Technology, Knowledge, and Innovation, Government of Chile; The Ministry of Foreign Affairs, Government of Chile, and the Chilean Public Health Institute (ISP). We also would like to thank Rami Scharf, Jessica White, Jorge Flores and Miren Iturriza-Gomara from PATH for their support on experimental design and discussion. Alex Cabrera and Sergio Bustos from the Flow Cytometry Facility at Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile for support with flow cytometry. We also thank the Vice Presidency of Research (VRI), the Direction of Technology Transfer and Development (DTD), the Legal Affairs Department (DAJ) of the Pontificia Universidad Católica de Chile. We are also grateful to the Administrative Directions of the School of Biological Sciences and the School of Medicine of the Pontificia Universidad Católica de Chile for their administrative support. We would also like to thank the members of the independent data safety monitoring committee (members in the SA) for their oversight, and the subjects enrolled in the study for their participation and commitment to this trial. This project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases,

National Institutes of Health, Department of Health and Human Services, under
Contract No. Contract No. 75N9301900065 to A.S, A.G. and D.W.

Note: Members of the CoronaVac03CL Study Group are listed in the
Supplementary Appendix (SA).

#### References

- 493 1. Mallapaty S. WHO approval of Chinese CoronaVac COVID vaccine will be
- 494 crucial to curbing pandemic [Internet]. Nature. 2021 [cited 2021 Oct
- 495 6];594(7862):161–2. Available from:
- 496 https://pubmed.ncbi.nlm.nih.gov/34089030/
- 497 2. Q G, L B, H M, et al. Development of an inactivated vaccine candidate for
- 498 SARS-CoV-2. Science [Internet] 2020 [cited 2021 Oct 6];369(6499):77–81.
- 499 Available from: https://pubmed.ncbi.nlm.nih.gov/32376603/
- 500 3. ZW, YH, MX, et al. Safety, tolerability, and immunogenicity of an
- inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60
- vears and older: a randomised, double-blind, placebo-controlled, phase 1/2
- clinical trial. Lancet Infect Dis [Internet] 2021 [cited 2021 Oct 6];21(6):803–
- 504 12. Available from: https://pubmed.ncbi.nlm.nih.gov/33548194/
- 505 4. Y Z, G Z, H P, et al. Safety, tolerability, and immunogenicity of an inactivated
- 506 SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised.
- double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis
- 508 [Internet] 2021 [cited 2021 Oct 6];21(2):181–92. Available from:
- 509 https://pubmed.ncbi.nlm.nih.gov/33217362/
- 510 5. SM B, K A, PA G, et al. Safety and Immunogenicity of an Inactivated SARS-
- 511 CoV-2 Vaccine in a Subgroup of Healthy Adults in Chile. Clin Infect Dis
- 512 [Internet] 2021 [cited 2021 Oct 9]; Available from:
- 513 https://pubmed.ncbi.nlm.nih.gov/34537835/
- 514 6. Sauré D, O'Ryan M, Torres JP, Zuniga M, Santelices E, Basso LJ. Dynamic
- 515 IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19

516 vaccines in Chile: a sentinel surveillance study. Lancet Infect Dis [Internet] 517 2021 [cited 2021 Oct 11];0(0). Available from: 518 http://www.thelancet.com/article/S1473309921004795/fulltext Duarte LF. Gálvez NMS. Iturriaga C. et al. Immune Profile and Clinical 519 7. 520 Outcome of Breakthrough Cases After Vaccination With an Inactivated 521 SARS-CoV-2 Vaccine. Front Immunol [Internet] 2021 [cited 2021 Oct 522 11];0:3884. Available from: 523 https://www.frontiersin.org/articles/10.3389/fimmu.2021.742914/full 524 8. Jara A, Undurraga EA, González C, et al. Effectiveness of an Inactivated 525 SARS-CoV-2 Vaccine in Chile. https://doi.org/101056/NEJMoa2107715 526 [Internet] 2021 [cited 2021 Oct 7];385(10):875–84. Available from: 527 https://www.nejm.org/doi/full/10.1056/NEJMoa2107715 528 9. Chile ha administrado más de 41 millones 980 mil dosis de vacuna contra 529 SARS-CoV-2 - Ministerio de Salud - Gobierno de Chile [Internet]. [cited 2021 530 Dec 10]:Available from: https://www.minsal.cl/chile-ha-administrado-mas-de-531 41-millones-980-mil-dosis-de-vacuna-contra-sars-cov-2/ 532 10. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are 533 highly predictive of immune protection from symptomatic SARS-CoV-2 534 infection. Nat Med 2021 277 [Internet] 2021 [cited 2021 Oct 6];27(7):1205-11. Available from: https://www.nature.com/articles/s41591-021-01377-8 535 536 11. Protection duration after vaccination or infection – Swiss National COVID-19 537 Science Task Force [Internet]. [cited 2021 Oct 6]; Available from: 538 https://sciencetaskforce.ch/en/policy-brief/protection-duration-after-539 vaccination-or-infection/

540 12. Pan H, Wu Q, Zeng G, et al. Immunogenicity and safety of a third dose, and 541 immune persistence of CoronaVac vaccine in healthy adults aged 18-59 542 years: interim results from a double-blind, randomized, placebo-controlled 543 phase 2 clinical trial, medRxiv [Internet] 2021 [cited 2021 Oct 544 6];2021.07.23.21261026. Available from: 545 https://www.medrxiv.org/content/10.1101/2021.07.23.21261026v1 546 13. Cao Y, Yisimayi A, Bai Y, et al. Humoral immune response to circulating 547 SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines. Cell Res 2021 317 [Internet] 2021 [cited 2021 Oct 8];31(7):732-41. Available 548 549 from: https://www.nature.com/articles/s41422-021-00514-9 550 Melo-González F, Soto JA, González LA, et al. Recognition of Variants of 14. 551 Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated 552 Vaccine. Front Immunol [Internet] 2021:12. Available from: https://www.frontiersin.org/articles/10.3389/fimmu.2021.747830/full 553 554 Clemens SAC, Weckx L, Clemens R, et al. Heterologous versus homologous 15. 555 COVID-19 booster vaccination in previous recipients of two doses of 556 CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-557 inferiority, single blind, randomised study. Lancet [Internet] 2022 [cited 2022] 558 Jan 24];0(0). Available from: http://www.thelancet.com/article/S0140673622000940/fulltext 559 560 16. Pérez-Then E, Lucas C, Monteiro VS, et al. Neutralizing antibodies against 561 the SARS-CoV-2 Delta and Omicron variants following heterologous 562 CoronaVac plus BNT162b2 booster vaccination. Nat Med 2022 [Internet] 563 2022 [cited 2022 Jan 24];1–1. Available from:

564 https://www.nature.com/articles/s41591-022-01705-6 565 17. Acevedo M, Alonso-Palomares L, Pantano S, Pasteur I, Navarrete M, Soto-566 Rifo R. Neutralization of the emerging SARS-CoV-2 variant Lambda by 567 antibodies elicited by inactivated virus and mRNA vaccines, 2021 [cited 2022] 568 Jan 31]; Available from: https://www.researchsquare.com 569 Depto Inmunizaciones D, De Prevención D, Control, Y Enfermedades S, 18. 570 Pública M de salud. DOSIS DE REFUERZO EN LA CAMPAÑA DE 571 VACUNACIÓN CONTRA SARS-COV-2 EN CHILE. 2021 [cited 2021 Oct 572 6]; Available from: https://www.minsal.cl/wp-573 19. Immunization Campaign against SARS-CoV-2 Early estimates of the 574 effectiveness of booster shots in Chile [Internet]. 2021 [cited 2021 Dec 575 10];Available from: https://www.minsal.cl/wp-content/uploads/2021/10/2021-576 10-07-EFECTIVIDAD-DOSIS-DE-REFUERZO ENG.pdf 577 World medical association. World Medical Association declaration of 20. 578 Helsinki: Ethical principles for medical research involving human subjects 579 [Internet]. JAMA - J. Am. Med. Assoc. 2013 [cited 2021 Oct 6];310(20):2191-580 4. Available from: https://pubmed.ncbi.nlm.nih.gov/24141714/ 581 21. WHO/BS.2020.2403 Establishment of the WHO International Standard and 582 Reference Panel for anti-SARS-CoV-2 antibody [Internet]. [cited 2021 Oct 583 8]; Available from: https://www.who.int/publications/m/item/WHO-BS-584 2020.2403 585 Acevedo ML, Alonso-Palomares L, Bustamante A, et al. Infectivity and 22. 586 immune escape of the new SARS-CoV-2 variant of interest Lambda. 587 medRxiv [Internet] 2021 [cited 2022 Jan 24];2021.06.28.21259673. Available

588 from: https://www.medrxiv.org/content/10.1101/2021.06.28.21259673v1 589 23. Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T Cell Responses to 590 SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and 591 Unexposed Individuals. Cell 2020;181(7):1489-1501.e15. 592 24. Lumley SF, O'Donnell D, Stoesser NE, et al. Antibody Status and Incidence 593 of SARS-CoV-2 Infection in Health Care Workers. 594 https://doi.org/101056/NEJMoa2034545 [Internet] 2020 [cited 2021 Oct 595 8];384(6):533–40. Available from: 596 https://www.nejm.org/doi/10.1056/NEJMoa2034545 597 25. Sabino EC, Buss LF, Carvalho MPS, et al. Resurgence of COVID-19 in 598 Manaus, Brazil, despite high seroprevalence. Lancet 2021;397(10273):452-599 5. 600 26. Wang K, Cao Y, Zhou Y, et al. A third dose of inactivated vaccine augments 601 the potency, breadth, and duration of anamnestic responses against SARS-602 CoV-2. medRxiv [Internet] 2021 [cited 2021 Oct 8];2021.09.02.21261735. 603 Available from: 604 https://www.medrxiv.org/content/10.1101/2021.09.02.21261735v1 605 27. Bar-On YM, Goldberg Y, Mandel M, et al. BNT162b2 vaccine booster dose 606 protection: A nationwide study from Israel. medRxiv [Internet] 2021 [cited 607 2021 Oct 8];2021.08.27.21262679. Available from: 608 https://www.medrxiv.org/content/10.1101/2021.08.27.21262679v1 609 Seyahi E, Bakhdiyarli G, Oztas M, et al. Antibody response to inactivated 28. 610 COVID-19 vaccine (CoronaVac) in immune-mediated diseases: a controlled 611 study among hospital workers and elderly. Rheumatol Int 2021 418 [Internet] 612 2021 [cited 2021 Oct 8];41(8):1429–40. Available from: 613 https://link.springer.com/article/10.1007/s00296-021-04910-7 614 Widge AT, Rouphael NG, Jackson LA, et al. Durability of Responses after 29. 615 SARS-CoV-2 mRNA-1273 Vaccination. 616 https://doi.org/101056/NEJMc2032195 [Internet] 2020 [cited 2021 Oct 617 8];384(1):80–2. Available from: 618 https://www.nejm.org/doi/full/10.1056/NEJMc2032195 619 30. Li M, Yang J, Wang L, et al. A booster dose is immunogenic and will be 620 needed for older adults who have completed two doses vaccination with 621 CoronaVac: a randomised, double-blind, placebo-controlled, phase 1/2 622 clinical trial. medRxiv [Internet] 2021 [cited 2021 Oct 623 8];2021.08.03.21261544. Available from: 624 https://www.medrxiv.org/content/10.1101/2021.08.03.21261544v1 Mateus J, Dan JM, Zhang Z, et al. Low-dose mRNA-1273 COVID-19 vaccine 625 31. generates durable memory enhanced by cross-reactive T cells. Science (80-626 627 ) [Internet] 2021 [cited 2021 Nov 11];374(6566). Available from: 628 https://www.science.org/doi/abs/10.1126/science.abj9853 629 32. Guerrera G, Picozza M, D'Orso S, et al. BNT162b2 vaccination induces 630 durable SARS-CoV-2 specific T cells with a stem cell memory phenotype. Sci Immunol [Internet] 2021 [cited 2021 Nov 11]; Available from: 631 632 https://www.science.org/doi/abs/10.1126/sciimmunol.abl5344 633 Cao Y, Hao X, Wang X, et al. Humoral immunogenicity and reactogenicity of 33. 634 CoronaVac or ZF2001 booster after two doses of inactivated vaccine. Cell 635 Res 2021 [Internet] 2021 [cited 2021 Dec 10];1–3. Available from:

636 https://www.nature.com/articles/s41422-021-00596-5 637 34. Viana R, Moyo S, Amoako DG, et al. Rapid epidemic expansion of the 638 SARS-CoV-2 Omicron variant in southern Africa. Nat 2022 [Internet] 2022 639 [cited 2022 Jan 31]:1–10. Available from: 640 https://www.nature.com/articles/s41586-022-04411-y 641 35. Hoffmann M, Krüger N, Schulz S, et al. The Omicron variant is highly 642 resistant against antibody-mediated neutralization: Implications for control of 643 the COVID-19 pandemic. Cell [Internet] 2021 [cited 2022 Jan 25]; Available from: https://linkinghub.elsevier.com/retrieve/pii/S0092867421014951 644 645 36. Ai J, Zhang H, Zhang Q, et al. Recombinant protein subunit vaccine booster 646 following two-dose inactivated vaccines dramatically enhanced anti-RBD 647 responses and neutralizing titers against SARS-CoV-2 and Variants of 648 Concern. Cell Res 2021 [Internet] 2021 [cited 2021 Dec 10]:1–4. Available from: https://www.nature.com/articles/s41422-021-00590-x 649 A T, J S, N M, et al. Impact of SARS-CoV-2 variants on the total CD4 + and 650 37. 651 CD8 + T cell reactivity in infected or vaccinated individuals. Cell reports Med 652 [Internet] 2021 [cited 2021 Oct 25];2(7). Available from: 653 https://pubmed.ncbi.nlm.nih.gov/34230917/ 654 Gao Y, Cai C, Grifoni A, et al. Ancestral SARS-CoV-2-specific T cells cross-38. 655 recognize the Omicron variant. Nat Med 2022 [Internet] 2022 [cited 2022 Jan 656 25];1-9. Available from: https://www.nature.com/articles/s41591-022-01700-657 Χ 658 659

## Figures legends

Figure 1: Study profile, enrolled volunteers, and cohort included in the study by November 11<sup>th</sup>, 2021. A. From the one hundred and eighty-six vaccinated individuals that received the booster dose, seventy-seven volunteers that received two doses of CoronaVac® in a 28 days interval (0-28 days schedule of vaccination), were selected from the center assigned for the immunogenicity study. Seventy-seven volunteers were tested for neutralizing antibodies by sVNT, sixty-two were selected to analyze neutralizing antibodies by cVNT and forty were selected to analyze cellular immunity. Analyses for immunity against SARS-CoV-2 variants were performed in 30 volunteers for sVNT, pVNT and T cells assays. B. Timeline of 0–28 days schedule of vaccination and booster dose immunization. Text in red denotes timepoints at which blood draws occurred.

Figure 2: Quantification of circulating antibodies inhibiting the interaction between the S1-RBD and hACE2 and in live SARS-CoV-2 in volunteers that received the booster dose of CoronaVac®. A-C. Inhibiting antibodies were detected in serum of volunteers immunized with CoronaVac® using a surrogate Viral Neutralization Test (sVNT), which quantifies the interaction between S1-RBD and hACE2 on ELISA plates. Results were obtained from a total of seventy-seven volunteers (A), thirty-six of them were adults between 18-59 years old (B), and forty-one of them were ≥ 60 years old (C). Data is represented as WHO arbitrary units/mL, the numbers above each set of individual data points show the Geometric Mean Units (GMU), the error bars indicate the 95% CI, and the number

685

686

687

688

689

690

691

692

693

694

695

696

697

698

699

700

701

702

703

704

705

706

at the right represents the fold increase of the GMU four weeks after the third dose as compared with the respective times after administration of the second dose. D-F. Neutralizing antibodies were detected in serum of volunteers that received a booster dose of CoronaVac® twenty weeks after the second dose, using a conventional Viral Neutralization Test (cVNT), which quantifies the reduction of cytopathic effect (CPE) in Vero E6 cells infected with SARS-CoV-2. Results were obtained from 62 volunteers (**D**), 30 of them were adults between 18-59 years old (E), and 32 of them were  $\geq$  60 years old (F). Data are expressed as the reciprocal of the highest serum dilution preventing 100% cytopathic effect, the numbers above each set of individual data points show the Geometric Mean Titer (GMT). the error bars indicate the 95% CI, and the number at the right represents the fold increase of the GMU the third dose + 4 weeks as compared with the respective times after administration of the second dose. CI were not adjusted for multiplicity and should not be used for inference. A repeated measures One-Way ANOVA test assessed statistical differences to compare all times against 3<sup>rd</sup> dose + four weeks. \*\*\*\*p<0.0001.

Figure 3: Changes in activation-induced markers (AIMs) expression in CD4<sup>+</sup> T cells and in the number of IFN-γ-secreting cells specific for SARS-CoV-2 after a booster dose of CoronaVac<sup>®</sup>. A-C. AIM<sup>+</sup> CD4<sup>+</sup> T cells were quantified in peripheral blood mononuclear cells of volunteers that received a booster dose of CoronaVac<sup>®</sup> twenty weeks after the second dose by flow cytometry, upon stimulation with mega-pools of peptides derived from SARS-CoV-2 proteins. The

708

709

710

711

712

713

714

715

716

717

718

719

720

721

722

723

724

725

726

727

728

729

percentage of activated AIM<sup>+</sup> CD4<sup>+</sup> T cells (OX40<sup>+</sup>, CD137<sup>+</sup>) were determined upon stimulation for 24h with MP-S+R in samples obtained at pre-immune, two weeks after the second dose, four weeks after the second dose, twenty weeks the second dose, and four weeks after the booster dose. Data from flow cytometry was normalized against DMSO and analyzed separately by a Friedman test against the booster dose. Results were obtained from a total of forty volunteers (A), twentyone were of them were adults between 18-59 years old (B), and nineteen of them were  $\geq$  60 years old (**C**). Changes in the secretion of IFN- $\gamma$  were quantified as the number of Spot Forming Cells (SFCs) in peripheral blood mononuclear cells of volunteers that received a booster dose of CoronaVac® 20 weeks after the second dose. **D-F**. Data was obtained upon stimulation with MP-S+R for 48h in samples obtained at pre-immune, two weeks after the second dose, four weeks after the second dose, twenty weeks the second dose, and four weeks after the booster dose. Results were obtained from a total of 40 volunteers (D), 21 were of them were adults between 18-59 years old (E), and 19 of them were  $\geq$  60 years old (F). Data from ELISPOT were analyzed separately by Friedman test against the booster dose \*p<0.05; \*\*p<0.005; \*\*\*p<<0.001; \*\*\*\*p<0.0001.

Figure 4: Quantification of circulating neutralizing antibodies against SARS-CoV-2 variants in volunteers that received the booster dose of CoronaVac®.

A. Neutralizing antibodies were detected in the serum of thirty volunteers, four weeks after the booster dose of CoronaVac®, using a pseudotyped virus neutralization test (pVNT). Data are expressed as the reciprocal of the highest

dilution preventing 80% of the infection (ID80). Numbers above the bars show the Mean, and the error bars indicate the 95% CI. The number at the right represents the fold decrease of the GMT four weeks after the booster dose as compared with the response of D614G **B**. Seropositivity rate of neutralizing antibodies is shown for each time point analyzed. Numbers above the bars show the percentage of seropositivity rate in the respective graphs. Numbers above the bars show the percentage of seropositivity rate in the respective graphs. A repeated measures One-Way ANOVA test assessed statistical differences of the GMT to compare each variant against D614G. \*p<0.05; \*\*\*\*p<0.001; \*\*\*\*\*p<0.0001

Figure 5: A booster dose of CoronaVac® induce changes in the number of IFN-γ-secreting cells and in activation-induced markers (AIMs) expression in CD4+ T cells specific for the Spike protein of SARS-CoV-2 variants. A. Changes in the secretion of IFN-γ, determined as the number of Spot Forming Cells (SFCs) were determined. Data was obtained upon stimulation of PBMC with MP-S of variant of concern of SARS-CoV-2 for 48h in samples obtained four weeks after the booster dose. Data shown represent mean + 95%CI. Data from thirty volunteers were analyzed at four weeks after the booster dose to compare among the MP-S of the variant of concern. Data from ELISPOT were analyzed separately by Friedman test against the WT MP-S. No significant differences were obtained.

B. AIM+ CD4+ T cells were quantified in peripheral blood mononuclear cells of thirty volunteers four weeks after that received a booster dose of CoronaVac® by flow

cytometry, upon stimulation with mega-pools of peptides derived from proteins of variant of concern of SARS-CoV-2. The percentage of activated AIM+ CD4+ T cells (OX40+, CD137+) were determined upon stimulation for 24h with MP-S+R in samples obtained four weeks after the booster dose. Data shown represent mean + 95%CI. Data from flow cytometry was normalized against DMSO. No significant differences were obtained between WT and the variant MP stimulation.

# Table

760

761

762763764

765

766 767

# Table 1: Demographic and clinical data of seventy-seven volunteers analyzed.

	Age group	AHT N (%)	AR N (%)	MD N (%)	Obesity N (%)	Insulin resistance N (%)	COPD N (%)	HT N (%)
Female sex N (%)	41 (53.2)	11 (14.3)	8 (10.4)	1 (1.3)	6 (7.8)	6 (7.8)	3 (3.9)	7 (9.1)
18-59 years old	18 (23.4)	3 (3.9)	6 (7.8)	0	2 (2.6)	3 (3.9)	0	2 (2.6)
≥60 years old	23 (30.0)	8 (10.4)	2 (2.6)	1 (1.3)	4 (5.2)	3 (3.9)	3 (3.9)	5 (6.5)
Male sex N (%)	36 (46.8)	11 (14.3)	8 (10.4)	3 (3.9)	11 (14.3)	1 (1.3)	0	1 (1.3)
18-59 years old	17 (22.0)	4 (5.2)	4 (5.2)	2 (2.6)	4 (5.2)	0	0	0
≥60 years old	19 (24.6)	7 ( 9.1)	4 (5.2)	1 (1.3)	7 (9.1)	1 (1.3)	0	1 (1.3)

Arterial hypertension: AHT; Chronic obstructive pulmonary disease: COPD; Mellitus diabetes: MD; Hypothyroidism: HT; Allergic rhinitis: AR

Table 2: Seropositivity rates, Geometric Mean Titer (GMT), and Geometric Mean Units (GMU) of circulating neutralizing antibodies against SARS-CoV-2 RBD.

Methodology	Age group	Indicators	2 <sup>nd</sup> dose + 2 weeks	2 <sup>nd</sup> dose + 4 weeks	2 <sup>nd</sup> dose + 20 weeks	3 <sup>rd</sup> dose + 4 weeks
	Total Vaccine	Seropositivity n/N	72/77	73/77	38/77	75/77
		(%)	93.5	94.8	49.4	97.4
		GMU	168.0	124.8	39.0	499.4
		95% CI	126.8- 222.5	96.3- 161.7	32.4-47.0	370.6- 673.0
		GMT	25.8	16.6	3.5	53.0
		95% CI	19.5-34.2	13.1-21.0	3.0-4.1	40.8-68.8
	18-59	Seropositivity n/N	35/36	36/36	24/36	36/36
		(%)	97.2	97.2	66.7	100
e)/NT		GMU	220.2	155.0	48.9	918.8
sVNT		95% CI	150.7- 321.7	108.0- 222.6	37.6-63.5	623.4- 1354
		GMT	33.3	19.1	4.3	82.8
		95% CI	23.4-47.3	14.0-26.1	3.4-5.4	59.7- 114.8
	≥60	Seropositivity n/N	38/41	39/42	15/42	40/42
		(%)	90.5	92.9	35.7	95.2
		GMU	134.1	104.1	32.4	300.5
		95% CI	89.2- 201.6	71.8- 151.0	25.1-41.8	203.5- 443.6
		GMT	20.8	14.7	2.4	36.5
		95% CI	13.6-31.9	10.3-21.0	2.4-3.5	25.3-52.7
cVNT	Total Vaccine	Seropositivity n/N	49/62	51/62	44/62	62/72
		(%)	79.0	82.3	71.0	100
		GMT	12.8	13.5	8.3	89.5
		95% CI	8.8-18.5	9.6-19.2	5.6-12.2	64.0- 125.2
	18-59	Seropositivity n/N	25/30	27/30	23/30	30/30
		(%)	83.3	90.0	76.7	100

		GMT	17.5	18.8	14.2	176.9
		95% CI	9.8-31.3	11.2-31.7	7.1-28.4	111.7- 280.1
		Seropositivity n/N	24/32	24/32	21/32	32/32
	≥60	(%)	75.0	75.0	65.6	100
		GMT	9.5	9.9	5.0	47.3
		95% CI	5.8-15.4	6.2-15.8	3.5-7.0	32.1-69.5

sVNT: Surrogate Virus Neutralization; cVNT: Conventional Virus Neutralization; GMT: Geometric mean titer; GMU: Geometric mean units.

Table 3: Seropositivity rates, Geometric Mean Titer (GMT) of circulating neutralizing antibodies against SARS-CoV-2 RBD of D614G and variants of concern (Delta and Omicron).

	Variant	D614G	Delta (B.1.617.2)	Omicron (B.1.1.529)	
pVNT	Indicators	3rd dose + 4 weeks	3rd dose + 4 weeks	3rd dose + 4 weeks	
	Seropositivity n/N	30/30	28/30	23/30	
	(%)	100	93.3	76.6	
	GMT	241.8	159.2	50.7	
	95% CI	155.7- 375.6	99.1-256.0	30.4-84.8	

GMT: Geometric mean titer.

# Figure 1









Figure 2















Figure 3







Figure 4






Figure 5

